Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Shanghai Ark Biopharmaceutical / Equity Capital Markets

<ul>
<li>ArkBIo, a China-based near-commercial-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. JPM and CITIC are the joint sponsors.</li>
<li>In our previous note, we looked at the company’s core products, AK0529 and AK3280. We also looked at the company’s pre-IPO investors and management team.</li>
<li>In this note, we look at updates in its latest prospectus and review the competitive landscape of its core products.</li>
</ul>


ArkBIo, a China-based near-commercial-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. JPM and CITIC are the joint sponsors.
In our previous note, we looked at the company’s core products, AK0529 and AK3280. We also looked at the company’s pre-IPO investors and management team.
In this note, we look at updates in its latest prospectus and review the competitive landscape of its core products.


ArkBio (爱科百发) Pre-IPO: PHIP Update Shows RSV on Track, IPF Bar Rises

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Zijin Gold International / Equity Capital Markets

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, <a href="https://www.smartkarma.com/entities/zijin-gold" target="_blank" data-smartkarma-citation="entities:45448:1" rel="noopener">Zijin Gold</a> appears to be shining bright.</li>
<li>On the placements front, it was a relatively quiter week, as compared to some of the more recent weekly flows.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, Zijin Gold appears to be shining bright.
On the placements front, it was a relatively quiter week, as compared to some of the more recent weekly flows.


ECM Weekly (22 September 2025)- Chery, Zijin Gold, Orion, Myungin, Urban, Avepoint, Dongfang

<ul>
<li>ArkBio, a China-based near commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. JPM and CITIC are the joint sponsors.</li>
<li>In this note, we look at the company’s core products, AK0529 and AK3280.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


ArkBio, a China-based near commercial stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. JPM and CITIC are the joint sponsors.
In this note, we look at the company’s core products, AK0529 and AK3280.
We also look at the company’s pre-IPO investors and management team.


ArkBio (爱科百发) Pre-IPO: Early Signs of Success for Recycled Assets

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<p>In the era of excessive competition of anti-tumor drugs, many enterprises began to make layout in other fields such as ophthalmologic drugs, respiratory drugs, dermatologic drugs, antiviral drugs and so on. On June 29<sup>th</sup>, 2021, <a href="https://www.smartkarma.com/entities/shanghai-ark-biopharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:33766:1" rel="noopener">Shanghai Ark Biopharmaceutical (SAB HK)</a> submitted its prospectus to the HKEX and officially started its IPO process. Ark is an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. This insight mainly analyzed the important product candidates in the pipeline and related concerns.</p>

In the era of excessive competition of anti-tumor drugs, many enterprises began to make layout in other fields such as ophthalmologic drugs, respiratory drugs, dermatologic drugs, antiviral drugs and so on. On June 29th, 2021, Shanghai Ark Biopharmaceutical (SAB HK) submitted its prospectus to the HKEX and officially started its IPO process. Ark is an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. This insight mainly analyzed the important product candidates in the pipeline and related concerns.

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Ark Biopharmaceutical (SAB HK)

ArkBio (爱科百发) Pre-IPO: PHIP Update Shows RSV on Track, IPF Bar Rises

ArkBio Pre-IPO: We look at its PHIP updates and further our analysis in competitive landscape analysis across RSV, IPF, and ADHD pipelines.

Ke Yan, CFA, FRM

ECM Weekly (22 September 2025)- Chery, Zijin Gold, Orion, Myungin, Urban, Avepoint, Dongfang

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

ArkBio (爱科百发) Pre-IPO: Early Signs of Success for Recycled Assets

ArkBio seeks to raise at least $100 million through a Hong Kong listing, with JPM and CITIC as joint sponsors. We look at their core products, pre...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

ArkBio (爱科百发) Pre-IPO: PHIP Update Shows RSV on Track, IPF Bar Rises

ArkBio Pre-IPO: We look at its PHIP updates and further our analysis in competitive landscape analysis across RSV, IPF, and ADHD pipelines.

Ke Yan, CFA, FRM

ECM Weekly (22 September 2025)- Chery, Zijin Gold, Orion, Myungin, Urban, Avepoint, Dongfang

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

ArkBio (爱科百发) Pre-IPO: Early Signs of Success for Recycled Assets

ArkBio seeks to raise at least $100 million through a Hong Kong listing, with JPM and CITIC as joint sponsors. We look at their core products, pre...

Ke Yan, CFA, FRM

Pre-IPO Shanghai Ark Biopharmaceutical - Insights on Pipeline and Related Concerns

The article mainly analyzed Ark Biopharmaceutical in terms of the important product candidates AK0529 (ziresovir) and AK3280 that entered the...

Xinyao (Criss) Wang